Therefore, we evaluated the change in the levels of serum asprosin after SGLT2 inhibitors treatment in patients diagnosed newly T2DM, which may benefit to explain its mechanisms for cardiovascular system protection. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.